Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.
Publication
, Conference
Crespin, DJ; Federspiel, J; Biddle, AK; Jonas, D; Stearns, SC; Rossi, JS
Duke Scholars
Conference Name
International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting
Citation
APA
Chicago
ICMJE
MLA
NLM
Crespin, D. J., Federspiel, J., Biddle, A. K., Jonas, D., Stearns, S. C., & Rossi, J. S. (n.d.). Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome. Presented at the International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting.
Crespin, D. J., Jeff Federspiel, A. K. Biddle, D. Jonas, S. C. Stearns, and J. S. Rossi. “Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.,” n.d.
Crespin DJ, Federspiel J, Biddle AK, Jonas D, Stearns SC, Rossi JS. Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome. In.
Crespin DJ, Federspiel J, Biddle AK, Jonas D, Stearns SC, Rossi JS. Cost-effectiveness of genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome.
Conference Name
International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting